Advertisement

Search Results

Advertisement



Your search for all items matches 2981 pages

Showing 1 - 50


lung cancer

David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease

David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the...

leukemia

Nicholas J. Short, MD: Focus on TP53-Mutated ALL

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur in 10% to 15% of adult patients with ALL. Dr. Short reviews recent research into their impact on...

leukemia

Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML

Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engaged in at the SOHO meeting. They discuss concomitant vs sequential use of lower-intensity regimens in ...

lung cancer

Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy

Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell...

leukemia

Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML

Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML). 

lung cancer

Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib

Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1...

lung cancer

Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib

Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the...

lung cancer

Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable...

lung cancer

John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract...

leukemia

Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL

Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretreated population of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and...

lung cancer

Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC

Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with...

leukemia

Farhad Ravandi, MD, on AML: Highlights of Ongoing Research

Farhad Ravandi, MD, provides an overview of acute myeloid leukemia (AML) research highlighted in a session at SOHO, including data on menin inhibitors in NPM1-mutated disease; FLT3 inhibitors in FLT3-mutated disease; IDH inhibitors in IDH1-mutated disease; the role of measurable residual disease;...

leukemia

Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL

Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem cell transplant, but received the chimeric antigen receptor (CAR) T-cell therapy obecabtagene...

breast cancer
cardio-oncology

Case 3: Cardiac Risk Stratification

This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...

breast cancer
cardio-oncology

Case 2: CDK4/6 Inhibitor Choice in Medically Fragile Patients With Heart Failure

This is Part 2 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss managing...

breast cancer
cardio-oncology

Case 1: Management of Cardiovascular Risk Factors

This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...

hematologic malignancies

Case 3: Patient With Myelofibrosis on Active Treatment

This is Part 3 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...

hematologic malignancies

Case 2: Patient With Myelofibrosis and Anemia

This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...

hematologic malignancies

Case 1: Patient With Newly Diagnosed Post-PV Myelofibrosis

This is Part 1 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of...

multiple myeloma

Case 3: Optimal Sequencing of T-Cell–Redirected Therapies

This is Part 3 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with high-risk...

multiple myeloma

Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma

This is Part 2 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed...

multiple myeloma

Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies

This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly...

colorectal cancer
genomics/genetics

Clinical Utility of Including ctDNA Monitoring in Standard-of-Care CRC Surveillance

Arvind N. Dasari, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses data presented at the ESMO Gastrointestinal Cancers Congress 2025, which showed that adding circulating tumor DNA (ctDNA) testing to current standard of care surveillance for patients with colorectal cancer...

genomics/genetics

MRD Testing: Recent Data and Ongoing Efforts

Circulating tumor DNA has many roles in cancer treatment: early diagnosis, tumor profiling, determining response to therapy, and tracking clinical dynamics. In this video, Arvind N. Dasari, MD, MS, of The University of Texas MD Anderson Cancer Center, focuses on it as a marker for measurable...

cns cancers

Case 3: High-Grade Astrocytoma

This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 2: Low-Grade Glioma

This is Part 2 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 1: Low-Grade Oligodendroglioma

This is Part 1 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade...

hepatobiliary cancer

Case 3: Fibrolamellar Hepatocellular Carcinoma

This is Part 3 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of fibrolamellar...

hepatobiliary cancer

Case 2: Advanced Hepatocellular Carcinoma

This is Part 2 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of advanced hepatocellular...

hepatobiliary cancer

Case 1: Metastatic Cholangiocarcinoma

This is Part 1 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of metastatic...

gynecologic cancers

Case 3: Low-Grade Platinum-Resistant Ovarian Cancer

This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of low-grade platinum-resistant...

gynecologic cancers

Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer

This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of HER2-positive...

gynecologic cancers

Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer

This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of high-grade platinum-resistant ...

lung cancer

Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer

This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell ...

lung cancer

Case 2: Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

This is Part 2 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of newly diagnosed extensive-stage...

lung cancer

Case 1: Relapsed Small Cell Lung Cancer

This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer...

breast cancer

Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...

prostate cancer

Case 3: Recurrent Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the management of recurrent...

prostate cancer

Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer

This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of high-risk de...

prostate cancer

Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency

This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of de novo...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 3: Radioligands in Advanced Neuroendocrine Tumor

This is Part 3 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the use of radioligand therapy for advanced...

neuroendocrine tumors
gastrointestinal cancer

Case 2: Well-Differentiated Grade 3 Small Bowel Neuroendocrine Tumor

This is Part 2 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of well-differentiated grade 3...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 1: Pancreatic Neuroendocrine Tumor

This is Part 1 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of pancreatic neuroendocrine...

Case 3: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 and PIK3CA Mutations

This is Part 3 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 64-year-old postmenopausal woman...

Case 2: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer and ESR1 D538G Mutation After Progression on CDK4/6 Inhibitor

This is Part 2 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 67-year-old postmenopausal woman...

breast cancer

Case 1: First-Line Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Y537S Mutation

This is Part 1 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 61-year-old female patient who...

breast cancer

Case 3: Leptomeningeal Disease in HER2-Positive Breast Cancer

This is Part 3 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

Case 2: Intracranial Progression on ADC Therapy

This is Part 2 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

breast cancer

Case 1: Isolated Brain Relapse in HER2-Positive Breast Cancer

This is Part 1 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a cT2N1,...

hematologic malignancies

Case 3: Managing Myelofibrosis Beyond the First-Line Setting

This is Part 3 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 70-year-old ...

Advertisement

Advertisement




Advertisement